Immunosuppressive glycoforms of soluble CD52

Leonard Charles Harrison; Esther Bandala Sanchez; Ethan David Goddard-Borger; Nicolle Hannah Packer; Shathili Abdulrahman Mansour

Immunosuppressive glycoforms of soluble CD52

Leonard Charles Harrison (Inventor), Esther Bandala Sanchez (Inventor), Ethan David Goddard-Borger (Inventor), Nicolle Hannah Packer (Inventor), Shathili Abdulrahman Mansour (Inventor)

Research output: Patent

Abstract

The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

Original language	English
Patent number	US2022185864
IPC	C07K 14/705,A61K 38/17,A61K 35/16,A61K 38/28
Priority date	7/03/19
Publication status	Submitted - 16 Jun 2022

Access to Document

https://patentscope.wipo.int/search/en/detail.jsf?docId=US365476713

2 Patent

Immunosuppressive glycoforms of soluble CD52
Harrison, L. C., Bandala-Sanchez, E., Goddard-Borger, E. D., Packer, N. H. & Mansour, S. A., 12 Jan 2022, (Submitted) IPC No. C07K 9/00, A61K 38/00, A61K 38/04, A61P 37/00, C07K 1/18, C07K 1/22, Patent No. EP3935073, Priority date 7 Mar 2019, Priority No. WO2019AU50197
Research output: Patent
Immunosuppressive glycoforms of soluble CD52
Harrison, L. C., Bandala-Sanchez, E., Goddard-Borger, E. D., Packer, N. H. & Shathili, A., 19 Mar 2020, IPC No. C07K 4/12, A61K 38/00, A61K 38/10, A61K 39/00, A61P 29/00, A61P 37/00, Patent No. AU2019201584, 7 Mar 2019, Priority date 7 Mar 2019
Research output: Patent

Cite this

@misc{2f564e4b40ae4e278cc4d10b2ed1d04e,

title = "Immunosuppressive glycoforms of soluble CD52",

abstract = "The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.",

author = "Harrison, {Leonard Charles} and {Bandala Sanchez}, Esther and Goddard-Borger, {Ethan David} and Packer, {Nicolle Hannah} and Mansour, {Shathili Abdulrahman}",

year = "2022",

month = jun,

day = "16",

language = "English",

type = "Patent",

note = "US2022185864; C07K 14/705,A61K 38/17,A61K 35/16,A61K 38/28",

}

TY - PAT

T1 - Immunosuppressive glycoforms of soluble CD52

AU - Harrison, Leonard Charles

AU - Bandala Sanchez, Esther

AU - Goddard-Borger, Ethan David

AU - Packer, Nicolle Hannah

AU - Mansour, Shathili Abdulrahman

PY - 2022/6/16

Y1 - 2022/6/16

N2 - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

AB - The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the preparation and purification of these proteins and their use in the suppression of effector T-cell function and/or immune response, such as in the treatment of diseases or conditions mediated by effector T-cell function.

M3 - Patent

M1 - US2022185864

ER -

Immunosuppressive glycoforms of soluble CD52

Abstract

Access to Document

Fingerprint

Research output